Chu LL, et al. - As Sjögren's syndrome is an autoimmune disease with multi-system involvement, researchers examined if systemic immunosuppression could improve signs and symptoms and prevent its progression. Searching five electronic databases (MEDLINE, EMBASE, CENTRAL, CLINICALTRIALS.GOV, WHO ICTRP) were searched to include randomized controlled trials they identified 32 trials evaluating 19 different medications. As per outcomes, potential improvement in salivary gland function could be achieved via reducing inflammation. They identified no differences for serious adverse events (AEs), however, there were increased withdrawals from AEs. Xerostomia and xerophthalmia did not improve consistently with any of the individual immunomodulatory drugs.